Yidao Biotechnology (Suzhou) Co., Ltd.

Phase I study stage Primary objective To evaluate the safety and tolerability of recombinant herpes zoster vaccine (CHO cells) in healthy adults. Secondary objective To evaluate the immunogenicity of recombinant herpes zoster vaccine (CHO cells) in healthy adults. Phase II study stage Primary objective To evaluate the immunogenicity of recombinant herpes zoster vaccine (CHO cells) in healthy adults. Secondary objective To further evaluate the safety of recombinant herpes zoster vaccine (CHO cells) in healthy adults.

Phase I study: The main purpose is to evaluate the safety of different doses of adjuvanted test vaccine inoculated in the population aged 18-45 years. The secondary purpose is to preliminarily explore the immunogenicity of different doses of adjuvanted test vaccine inoculated in the population aged 18-45 years. The purpose of Phase II study: To evaluate the immunogenicity and safety of different doses of adjuvanted test vaccine inoculated in female population aged 18-45 years according to two immunization schedules of 0, 2 months or 0, 6 months, and to explore the optimal ratio of adjuvant dose and immunization schedule.

Primary objective: To evaluate the protective efficacy of recombinant herpes zoster vaccine (Zoster, HZ) after full vaccination for 15 days. Secondary objectives: To evaluate the safety of recombinant herpes zoster vaccine (Zoster); To evaluate the immunogenicity of recombinant herpes zoster vaccine (Zoster); To evaluate the protective efficacy of recombinant herpes zoster vaccine (Zoster) after 15 days of vaccination for preventing any degree of postherpetic neuralgia (PHN) (ZBPI score ＞0) and severe PHN (grade ≥3).